For moderate to severe rheumatoid arthritis (RA) in adult TNFi-IR patients1

Older woman in a harness, ziplining

A once-daily
oral therapy studied
with
or without MTX1

IR=intolerance or inadequate response; MTX=methotrexate

One Pill‑Once A Day.1

RINVOQ is a 15 mg extended-release pill that may be used alone as monotherapy or in combination with methotrexate or other nonbiologic DMARDs1

For moderate to severe rheumatoid arthritis (RA) in adult
TNFi-IR patients:1

  • Take one pill at about the same time each day.
  • Ensure pill is taken whole. Do not break, crush, or chew.
  • Can be taken with or without food.
  • Store at 36˚F to 77˚F (2˚C to 25˚C) in the original bottle in order to protect from moisture.
  • In clinical trials, RINVOQ mean terminal elimination half-life ranged from 8-14 hours.
RINVOQ pill bottle and tablet
RINVOQ National Drug Code number: 0074-2306-30
One easy-to-open bottle

Awarded the Arthritis Foundation Ease of Use Commendation,2 our innovative bottle cap includes:

  • Wide, easy-to-grip texture
  • Embedded tool that seamlessly punctures the foil liner to simplify medication access
Arthritis Foundation Ease of Use

IR=intolerance or inadequate response

Lab Monitoring
and treatment considerations1

Lab monitoring Lab monitoring Lab monitoring

Treatment with RINVOQ should not be initiated, or should be interrupted if:

Absolute lymphocyte count <500 cells/mm3*; Absolute neutrophil count <1000 cells/mm3*; Hemoglobin levels <8 g/dL*; Elevated hepatic transaminases and drug-induced liver injury is suspected; Patient develops a serious infection* Absolute lymphocyte count <500 cells/mm3*; Absolute neutrophil count <1000 cells/mm3*; Hemoglobin levels <8 g/dL*; Elevated hepatic transaminases and drug-induced liver injury is suspected; Patient develops a serious infection* Absolute lymphocyte count <500 cells/mm3*; Absolute neutrophil count <1000 cells/mm3*; Hemoglobin levels <8 g/dL*; Elevated hepatic transaminases and drug-induced liver injury is suspected; Patient develops a serious infection*

*Treatment can be initiated or restarted after levels return above specified values, drug-induced liver injury diagnosis is excluded, or infection is controlled.

No dose adjustment is required for mild, moderate, or severe renal impairment.1

No dose adjustment is required for mild or moderate hepatic impairment.1

RINVOQ has not been studied in subjects with end stage renal disease.1

RINVOQ is not recommended for use in patients with severe hepatic impairment.1

Serious Infections:1 Closely monitor patients for the development of signs and symptoms of infection during and after treatment with RINVOQ.

Tuberculosis:1 Monitor patients for the development of signs and symptoms of TB, including patients who tested negative for latent TB infection prior to initiating therapy.

Viral Reactivation:1 Screening for viral hepatitis and monitoring for reactivation should be performed in accordance with clinical guidelines before starting and during therapy with RINVOQ.

Embryo-Fetal Toxicity:1 Based on animal studies, RINVOQ may cause fetal harm when administered to pregnant women. Verify pregnancy status prior to starting treatment. Advise women to use effective contraception during and for 4 weeks after completion of treatment.

Rinvoq is a JAK inhibitor1

Why JAKs are important in RA3-7

Pro-inflammatory cytokines use immune signaling networks, such as the JAK-STAT pathway, to communicate with the cell nucleus. When dysregulated, as in RA, these signals increase the inflammatory response, leading to cycles of chronic inflammation, presenting as pain, swelling, and progressive joint destruction.

Overview of the JAK-STAT pathway3,4,6,8,9

  1. A cytokine binds to a specific receptor on the cell surface...
  2. ...triggering JAK recruitment and activation inside the cell.
  3. The activated JAKs recruit and activate STATs...
  4. ...which in turn transmit the signal into the cell nucleus...
  5. ...initiating an inflammatory response that continues the cycle of pathologic inflammation.
JAK and cytokine pairings

The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.

RINVOQ is a JAK inhibitor

By inactivating JAK, RINVOQ is thought to block the recruitment, phosphorylation, and activation of STATs preventing the pro‑inflammatory cytokine signal from reaching the nucleus and inhibiting pro‑inflammatory processes associated with the JAK‑STAT pathway.

The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.

IL=interleukin; JAK=Janus Kinase; RA=rheumatoid arthritis; STAT=signal transducer and activator of transcription; TYK2=tyrosine kinase 2

RINVOQ™ COMPLETE

Discover how RINVOQ Complete can provide
exceptional access and product support